Reneuron Share News (RENE)

ReNeuron says exosomes outperform alternatives at Boston summit

(Alliance News) - ReNeuron Group PLC on Friday said it presented positive new data at a leading summit of targeted therapies.

IN BRIEF: ReNeuron promotes Financial Controller Hawkins to CFO

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Promotes Financial Controller John Hawkins to chief financial officer with immediate effect. Hawkins joined the company in 2014 as financial controller and was also named as the company secretary last year. Says Hawkins is an experienced finance professional with a breadth of experience gained within "a variety of businesses, from large PLCs to family-owned SMEs".

UK shareholder meetings calendar - next 7 days

EXECUTIVE CHANGES: ReNeuron promotes CFO Catherine Isted to CEO role

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

IN BRIEF: ReNeuron annual loss narrows amid shift in strategy

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Pretax loss in year to March 31 narrows to GBP11.1 million from GBP13.4 million loss a year prior. Research & development costs fall to GBP8.1 million from GBP9.5 million, with general & administrative costs at GBP3.6 million versus GBP3.7 million. Revenue drops to GBP403,000 from GBP257,000.

IN BRIEF: ReNeuron inks deal worth up to GBP6 million in revenue

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Negotiates a supplemental terms agreement with Shanghai Fosun Pharmaceutical Group Co Ltd. Company says the agreement has the potential to generate revenue of up to GBP6 million.

UK earnings, trading statements calendar - next 7 days

IN BRIEF: ReNeuron chair steps in to run business as CEO resigns

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology - Olav Hellobo resigns as chief executive officer after seven years and will leave at the end of February. Hellobo says he decided it was time to leave following ReNeuron's recent change in strategy. The company has shifted its focus to the development of its exosomes technology platform. The platform uses stem cell technologies to develop "off the shelf" treatments for diseases. Chair Iain Ross, supported by Chief Financial Officer Catherine Isted, will run the business, ReNeuron says.

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

ReNeuron shares dive as it drops retinitis pigmentosa trials

ReNeuron shares dive as it drops retinitis pigmentosa trials

TRADING UPDATES: Power Metal renewal; Yamana production hits target

TRADING UPDATES: Power Metal renewal; Yamana production hits target

ReNeuron re-appoints Randolph Corteling in senior research role

ReNeuron re-appoints Randolph Corteling in senior research role

TRADING UPDATES: Zambeef sales continue climb; Watchstone files claim

TRADING UPDATES: Zambeef sales continue climb; Watchstone files claim

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills

TRADING UPDATES: Symphony Environmental's India foray; Panthera drills